{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:17:54Z","timestamp":1772551074414,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.arteri.2021.02.013","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T07:32:04Z","timestamp":1617348724000},"page":"314-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rol de nuevos f\u00e1rmacos antidiab\u00e9ticos en prevenci\u00f3n cardiovascular e insuficiencia cardiaca"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-7939","authenticated-orcid":false,"given":"Jes\u00fas Miguel","family":"Rojas-Vel\u00e1zquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7683-4963","authenticated-orcid":false,"given":"Alejandro","family":"Giralt-Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2413-9536","authenticated-orcid":false,"given":"Jessica","family":"Leiva-Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Leiva-Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2021.02.013_bib0270","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2021. Diabetes Care. 2021; 44(Suppl. 1). Disponible en: https:\/\/care.diabetesjournals.org\/content\/44\/Supplement_1 [consultado 12 Feb 2021].","DOI":"10.2337\/dc21-Srev"},{"key":"10.1016\/j.arteri.2021.02.013_bib0275","first-page":"235","article-title":"Nuevos f\u00e1rmacos en diabetes mellitus","volume":"27","author":"Aylwin","year":"2016","journal-title":"REV. MED. CLIN. CONDES."},{"issue":"S2","key":"10.1016\/j.arteri.2021.02.013_bib0280","first-page":"12","article-title":"De la diabetes a la insuficiencia cardiaca. \u00bfExiste la miocardiopat\u00eda diab\u00e9tica?","volume":"27","author":"Saldarriaga-Giraldo","year":"2020","journal-title":"Rev Colomb Cardiol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0285","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/CIRCULATIONAHA.120.046783","article-title":"Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings","volume":"142","author":"Wright","year":"2020","journal-title":"Circulation."},{"issue":"S2","key":"10.1016\/j.arteri.2021.02.013_bib0290","first-page":"22","article-title":"Mecanismos de acci\u00f3n de los inhibidores de cotransportador de sodio y glucosa tipo 2-SGLT2-: M\u00e1s all\u00e1 del control de la glicemia","volume":"27","author":"Buitrago","year":"2020","journal-title":"Rev Colomb Cardiol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0295","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2021.02.013_bib0300","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0305","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0315","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0320","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0325","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0330","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0335","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0340","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","author":"Bhatt","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0345","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","author":"Bhatt","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0350","first-page":"831","article-title":"Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes","volume":"4","author":"Iborra-Egea","year":"2019","journal-title":"J Am Coll Cardiol Basic Trans Science."},{"key":"10.1016\/j.arteri.2021.02.013_bib0355","first-page":"27","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"J Am Coll Cardiol Basic Trans Science."},{"key":"10.1016\/j.arteri.2021.02.013_bib0360","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0365","article-title":"Randomized trial of empagliflozin in non-diabetic patients with heart failure and reduced ejection fraction","author":"Santos-Gallego","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0370","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2021.02.013_bib0375","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2019.11.016","article-title":"High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment","volume":"292","author":"Couselo-Seijas","year":"2020","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2021.02.013_bib0380","first-page":"601","article-title":"Agonistas de GLP-1 m\u00e1s inhibidores de SGLT2. \u00bfEfectos cardioprotectores aditivos?","volume":"34","author":"Matta-Herrera","year":"2018","journal-title":"Med Int M\u00e9x."},{"key":"10.1016\/j.arteri.2021.02.013_bib0385","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jdiacomp.2016.10.003","article-title":"Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes","volume":"31","author":"Scalzo","year":"2017","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.arteri.2021.02.013_bib0390","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0395","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0400","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0405","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0410","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","author":"Hernandez","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2021.02.013_bib0415","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2021.02.013_bib0420","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","article-title":"Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes","volume":"17","author":"Lambadiari","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0425","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12933-016-0425-2","article-title":"Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: A randomized double-blind placebo-controlled crossover study","volume":"15","author":"Kumarathurai","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0430","first-page":"559","article-title":"Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction","volume":"4","author":"Lepore","year":"2016","journal-title":"J Am Coll Cardiol HF."},{"key":"10.1016\/j.arteri.2021.02.013_bib0435","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0440","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0445","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0450","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2021.02.013_bib0455","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.9778\/cmajo.20160058","article-title":"Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A systematic review and meta-analysis","volume":"5","author":"Verma","year":"2017","journal-title":"CMAJ Open."},{"key":"10.1016\/j.arteri.2021.02.013_bib0460","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jval.2017.04.010","article-title":"Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A network meta-analysis","volume":"20","author":"Guo","year":"2017","journal-title":"Value Health."},{"key":"10.1016\/j.arteri.2021.02.013_bib0465","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jjcc.2016.08.011","article-title":"Effect of sitagliptin on plaque changes in coronary artery following acute coronary syndrome in diabetic patients: The ESPECIAL-ACS study","volume":"69","author":"Kuramitsu","year":"2017","journal-title":"J Cardiol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0470","doi-asserted-by":"crossref","first-page":"e1002051","DOI":"10.1371\/journal.pmed.1002051","article-title":"The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: The PROLOGUE randomized controlled trial","volume":"13","author":"Oyama J-i","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.arteri.2021.02.013_bib0475","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-016-0472-8","article-title":"Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: A sub-analysis of the PROLOGUE study","volume":"15","author":"Tomiyama","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0480","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-017-0546-2","article-title":"Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: A subgroup analysis of the PROLOGUE study","volume":"16","author":"Yamada","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0485","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-020-01061-0","article-title":"Treatment with anagliptin, a DPP-4 inhibitor decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy","volume":"19","author":"Furuhashi","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0490","first-page":"823","article-title":"Comparison of new glucose-lowering drugs on risk of heart failure in type 2 diabetes. A network meta-analysis","volume":"6","author":"Kramer","year":"2018","journal-title":"J Am Coll Cardiol HF."},{"key":"10.1016\/j.arteri.2021.02.013_bib0495","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2021.02.013_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-016-0432-4","article-title":"Cardiovascular safety of incretin-based therapies in type 2 diabetes: Systematic review of integrated analyses and randomized controlled trials","volume":"34","author":"Mannucci","year":"2017","journal-title":"Adv Ther."},{"key":"10.1016\/j.arteri.2021.02.013_bib0505","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","article-title":"Cardiovascular outcomes in trials of new antidiabetic drug classes: A network meta-analysis","volume":"18","author":"Fei","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arteri.2021.02.013_bib0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jendso\/bvaa037","article-title":"Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter inhibitors for treatment of T2DM","volume":"4","author":"McKee","year":"2020","journal-title":"J Endocr Soc."},{"key":"10.1016\/j.arteri.2021.02.013_bib0515","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2021.02.013_bib0520","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1232583","article-title":"Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: A systematic review and meta-analysis","author":"Batzias","year":"2018","journal-title":"J Diabetes Res."},{"key":"10.1016\/j.arteri.2021.02.013_bib0525","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care. A first analysis from the EMPRISE study","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2021.02.013_bib0530","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs. The CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:32:50Z","timestamp":1759325570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916821000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0214916821000516"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2021.02.013","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rol de nuevos f\u00e1rmacos antidiab\u00e9ticos en prevenci\u00f3n cardiovascular e insuficiencia cardiaca","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2021.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}